Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• Shares saw unusually high trading volume of about 1.27M shares and were up roughly 4.2%, trading near $15.11 versus a prior close of $14.54.
• Analysts are broadly positive with an average rating of Buy (2 Strong Buy, 9 Buy, 1 Sell) and an average price target of $21.60.
• Trevi is a clinical-stage biopharma developing a tetrodotoxin (TTX) non-opioid pain candidate; the company has a market cap of ~$1.95B, reported a quarterly EPS beat (‑$0.06 vs. estimate ‑$0.10), and institutional investors own about 95.76% of the stock.

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 1,271,739 shares changed hands during mid-day trading, a decline of 6% from the previous session's volume of 1,349,267 shares.The stock last traded at $15.1110 and had previously closed at $14.54.

Analyst Ratings Changes

Several equities analysts have recently commented on TRVI shares. Stifel Nicolaus boosted their target price on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, December 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Trevi Therapeutics in a research note on Wednesday, January 21st. D. Boral Capital reissued a "buy" rating and set a $19.00 price objective on shares of Trevi Therapeutics in a report on Friday. Oppenheimer reaffirmed an "outperform" rating on shares of Trevi Therapeutics in a report on Monday, March 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Trevi Therapeutics has an average rating of "Buy" and an average target price of $21.60.

Trevi Therapeutics Stock Up 4.2%

The business's fifty day moving average is $11.75 and its two-hundred day moving average is $11.51. The stock has a market capitalization of $1.95 billion, a PE ratio of -47.51 and a beta of 0.99.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.04. Sell-side analysts expect that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TRVI. Diversified Trust Co increased its stake in Trevi Therapeutics by 11.9% during the first quarter. Diversified Trust Co now owns 23,477 shares of the company's stock worth $280,000 after acquiring an additional 2,493 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Trevi Therapeutics in the 4th quarter worth approximately $50,000. Seven Fleet Capital Management LP purchased a new position in shares of Trevi Therapeutics in the 4th quarter worth approximately $89,000. Invesco Ltd. increased its position in shares of Trevi Therapeutics by 3.3% during the 4th quarter. Invesco Ltd. now owns 498,926 shares of the company's stock valued at $6,247,000 after purchasing an additional 15,856 shares during the last quarter. Finally, KVP Capital Advisors LP bought a new position in shares of Trevi Therapeutics during the 4th quarter valued at approximately $5,183,000. Hedge funds and other institutional investors own 95.76% of the company's stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.